Page last updated: 2024-09-03

sr 48692 and Carcinoma, Ductal, Pancreatic

sr 48692 has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cui, L; Li, HN; Li, NN; Wang, JG; Wang, P	1

Other Studies

1 other study(ies) available for sr 48692 and Carcinoma, Ductal, Pancreatic

Article	Year
Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. Neuropeptides, 2011, Volume: 45, Issue:2 Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Female; Humans; Male; Neurotensin; Pancreatic Neoplasms; Pyrazoles; Quinolines; Receptors, Neurotensin	2011

Article

Year

Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1.

Neuropeptides, 2011, Volume: 45, Issue:2

Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Female; Humans; Male; Neurotensin; Pancreatic Neoplasms; Pyrazoles; Quinolines; Receptors, Neurotensin

2011